Drug Trial Radar · NCT01712789
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
682
Actual
Start
Nov 6, 2012
Primary completion
Dec 11, 2019
Study completion Dec 11, 2019
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years. In addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses. The exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.
Conditions
- Multiple Myeloma
Interventions
PomalidomideDrug
Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
DexamethasoneDrug
Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
Locations
112 sites in 20 countries. Site status is shown where the registry gives one.
Medical University of Graz
Graz, Austria
Medizinische Universitat Innsbruck
Innsbruck, Austria
Wilhelminenspital Vienna
Vienna, Austria
Medical University of Vienna
Vienna, Austria
AZ St-Jan Brugge Oostende AV
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
VUB Vrije Universiteit Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liege
Liège, Belgium
CHU Mont -Godinne
Yvoir, Belgium
Aarhus University Hospital
Aarhus, Denmark
Odense University Hospital
Odense, Denmark
Vejle Hospital
Vejle, Denmark
Tartu University Hospital Clinic
Tartu, Estonia
Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Turku University Hospital
Turku, Finland
Centre Hospitalier de la cote basque
Bayonne, France
Hopital Henri Mondor
Créteil, France
Hopital A. Michallon
La Tronche, France
CHRU Claude Huriez
Lille, France
Institut Paoli Calmette Hematologie
Marseille, France
CHU Hotel Dieu
Nantes, France
Hopital Saint Antoine
Paris, France
Service Hemato-Immunologie Hopital St Louis
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU de Reims
Reims, France
Hematologie - CHU Purpan
Toulouse, France
CHRU Hopital Bretonneau
Tours, France
CHU Nancy Hematology
Vandœuvre-lès-Nancy, France
Charite, Campus Benjamin Franklin Universitatsmedizin Berlin
Berlin, Germany
Klinikum Chemnitz
Chemnitz, Germany
Klinikum der Universitat zu Koln
Cologne, Germany
Universitatsklinikum Carl Gustav Carus
Dresden, Germany
Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie
Düsseldorf, Germany
Universitatsklinikum Essen-
Essen, Germany
Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik
Freiburg im Breisgau, Germany
Abt Haematologie - Onkologie / Allg. Krankenhaus Altona
Hamburg, Germany
Universitatsklinikum Heidelberg
Heidelberg, Germany
Universitatsklinikum Jena
Jena, Germany
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.